Startups
Celonic Group is a privately owned CDMO with two state-of-the-art sites located at Basel (headquarters), Switzerland and Heidelberg, Germany.
Providing comprehensive GMP development and manufacturing services for New Biological Entities (NBEs) and Biosimilars, worldwide, and Cell Therapy & Gene associated services worldwide.
Celonic’s services include the development of cell lines, production processes, as well as non-GMP and GMP manufacturing of biopharmaceutical drug substances and drug product.
To complement their services with cell line development, Celonic uses its proprietary CHOvolution™ cell line technology and the human cell line GEX® for your easy or difficult target.
Being part of the JRS Pharma family, Celonic is a strong believer in creating win-win value propositions for the clients, mitigating risks by mutually-beneficial business models.
Celonic is ambitious, driven by the courage to think big and the commitment to get it done.
Celonic services covered:
2 INDUSTRY LEADING CELL EXPRESSION PLATFORMS:
CHOvolution™:
- Powered by Celonic's proprietary SEFEX™ technology
- Cell line based on CHO-K1 (non-genetically modified CHO)
- Cell line adapted to serum-free EMA and FDA compliant media
- Simplified licensing model (no royalties from sales)
- High productivity (>7 g/l for mABs)
GEX®:
- Human cells for fully-human glycosylation
- Optimized for complex and sophisticated biopharmaceutical products
- Stable product quality over full run-time for R&D and/or GMP
- High productivity (up to 22g/l bioreactor volume for mAbs )
PROCESS DEVELOPMENT:
- State-of-art USP and DSP development
- Cutting-edge, in-house, and high throughput bioanalytics
- Robust and scalable
BIOMANUFACTURING CAPACITIES:
- Two facilities (Germany and Basel)
- Up to 2,000 L capacity batches in GMP and R&D setup
- In-house analytics
- Swissmedic GMP certified
- 20 years of optimizing perfusion technique with >100 GMP batches
FILL & FINISH:
- Up to 1,250 vials/batch -Semi-automatic aseptic filling of liquids
- > 300 Fill & Finish campaigns
- Labeling packaging and storage of clinical test samples
- Compliance with FDA & EMA standards
NEW BIOLOGICAL ENTITIES :
Celonic offers comprehensive approaches to enable clients to achieve commercial success, with a proven track record of developing breakthrough biologics and delivering GMP batches of ex. mABs, Growth Hormones, Fusion Proteins, and Blood Factors.
BIOSIMILARS :
Celonic offers ready-to-go Biosimilars (cell lines and cell pools—comprehensive analytics methods, comparability data, and development process) shaped on co-development and co-investment of next wave Biosimilars.
EMPATHIE - EFFICIENCY - EXCELLENCE
That's Celonic. Learn more about us.
Providing comprehensive GMP development and manufacturing services for New Biological Entities (NBEs) and Biosimilars, worldwide, and Cell Therapy & Gene associated services worldwide.
Celonic’s services include the development of cell lines, production processes, as well as non-GMP and GMP manufacturing of biopharmaceutical drug substances and drug product.
To complement their services with cell line development, Celonic uses its proprietary CHOvolution™ cell line technology and the human cell line GEX® for your easy or difficult target.
Being part of the JRS Pharma family, Celonic is a strong believer in creating win-win value propositions for the clients, mitigating risks by mutually-beneficial business models.
Celonic is ambitious, driven by the courage to think big and the commitment to get it done.
Celonic services covered:
2 INDUSTRY LEADING CELL EXPRESSION PLATFORMS:
CHOvolution™:
- Powered by Celonic's proprietary SEFEX™ technology
- Cell line based on CHO-K1 (non-genetically modified CHO)
- Cell line adapted to serum-free EMA and FDA compliant media
- Simplified licensing model (no royalties from sales)
- High productivity (>7 g/l for mABs)
GEX®:
- Human cells for fully-human glycosylation
- Optimized for complex and sophisticated biopharmaceutical products
- Stable product quality over full run-time for R&D and/or GMP
- High productivity (up to 22g/l bioreactor volume for mAbs )
PROCESS DEVELOPMENT:
- State-of-art USP and DSP development
- Cutting-edge, in-house, and high throughput bioanalytics
- Robust and scalable
BIOMANUFACTURING CAPACITIES:
- Two facilities (Germany and Basel)
- Up to 2,000 L capacity batches in GMP and R&D setup
- In-house analytics
- Swissmedic GMP certified
- 20 years of optimizing perfusion technique with >100 GMP batches
FILL & FINISH:
- Up to 1,250 vials/batch -Semi-automatic aseptic filling of liquids
- > 300 Fill & Finish campaigns
- Labeling packaging and storage of clinical test samples
- Compliance with FDA & EMA standards
NEW BIOLOGICAL ENTITIES :
Celonic offers comprehensive approaches to enable clients to achieve commercial success, with a proven track record of developing breakthrough biologics and delivering GMP batches of ex. mABs, Growth Hormones, Fusion Proteins, and Blood Factors.
BIOSIMILARS :
Celonic offers ready-to-go Biosimilars (cell lines and cell pools—comprehensive analytics methods, comparability data, and development process) shaped on co-development and co-investment of next wave Biosimilars.
EMPATHIE - EFFICIENCY - EXCELLENCE
That's Celonic. Learn more about us.
Overview
Location
Switzerland, Basel-City, Basel
Employees
201-500
Founded date
1982
Mentions in press and media 4
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Mar 3, 2021 | As allogeneic cell therapy approaches flourish, Century loads up $160M to scale iPSC platform for CAR-T, CAR-NK | Lalo Flores is confident he’s found the way forward in cell therapy. The feeling, to be sure, is not exclusive. Thanks to splashy companies like Allogene, Lyell and Artiva, biopharma is well aware of the promises of allo... |
| Mar 3, 2021 | Swiss CDMO Celonic finds a home at Novartis' Stein hub, plans to add 250 new jobs centered on next-gen drugs | Bob Nelsen’s new, state-of-the-art drug manufacturing initiative is taking shape. Just 3 months after gathering $800 million of launch money, a dream team board and a plan to shake up a field where he found too many bottlenecks and ineffici... |
| Feb 20, 2018 | Projects with Swiss start-ups receive €18.5 million Eurostars-2 funding |
Reviews 0
FAQ about Celonic Group
When was Celonic Group founded?
Celonic Group was founded in 1982.
What has the press written about Celonic Group?
Parsers VC has collected 4 articles mentioning Celonic Group, among them “As allogeneic cell therapy approaches flourish, Century loads up $160M to scale iPSC platform for CAR-T, CAR-NK” (Mar 3, 2021) and “Swiss CDMO Celonic finds a home at Novartis' Stein hub, plans to add 250 new jobs centered on next-gen drugs” (Mar 3, 2021).
Is Celonic Group still active?
Yes, Celonic Group is active; its latest activity on Parsers VC dates from Mar 3, 2021.